Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: A matched-pair analysis

Journal of Surgical Oncology

Volumn 107, Issue 6, 2013, Pages 574-578

  Glockzin, Gabriel ^a   Von Breitenbuch, Philipp ^a   Schlitt, Hans J ^a   Piso, Pompiliu ^a,b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Saint John of God Hospital Regensburg   (Germany)

Author keywords

complications; HIPEC; morbidity; oxaliplatin; peritoneal carcinomatosis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CEFTRIAXONE; CYTOSTATIC AGENT; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; LOW MOLECULAR WEIGHT HEPARIN; METRONIDAZOLE; MITOMYCIN; OXALIPLATIN;

ABDOMINAL ABSCESS; ADULT; ANASTOMOSIS LEAKAGE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BILE LEAKAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOSIS; COLONOSCOPY; COMPRESSION STOCKING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; HEART ARRHYTHMIA; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; ILEUS; INTESTINE PERFORATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIPLE ORGAN FAILURE; OPERATION DURATION; PANCREATITIS; PERITONEAL CARCINOMATOSIS; PERITONEUM CANCER; PLEURA EFFUSION; PNEUMONIA; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; THROMBOSIS; TOXICITY; TUMOR LOCALIZATION; UMBILICAL NECROSIS; URINE RETENTION; WOUND INFECTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; LENGTH OF STAY; LEUCOVORIN; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MITOMYCIN; OPERATIVE TIME; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PERITONEUM; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84876405927     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23228     Document Type: Article

References (33)

1. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363.
2. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989; 16: 83-97.
3. Sugarbaker PH,: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006; 7: 69-76.
4. Glehen O, Gilly FN, Boutitie F, et al.: Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients. Cancer 2010; 116: 5608-5618.
5. Pilati P, Mocellin S, Rossi CR, et al.: Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003; 10: 508-513.
6. Glehen O, Cotte E, Schreiber V, et al.: Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91: 747-754.
7. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22: 3284-3292.
8. Shen P, Hawksworth J, Lovato J, et al.: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004; 11: 178-186.
9. Verwaal VJ, Bruin S, Boot H, et al.: 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432.
10. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743.
11. Quenet F, Claus C, Roca L, et al.: Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from digestive tract cancer-New management with oxaliplatin plus irinotecan: A feasibility study in 37 patients. J Clin Oncol 2008; 26: abstr. 4084.
12. Elias D, Lefevre JH, Chevalier J, et al.: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
13. Folprecht G, Gruenberger T, Bechstein WO, et al.: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.
14. Bokemeyer C, Bondarenko I, Makhson A, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
15. Falcone A, Ricci S, Brunetti I, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
16. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
17. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
18. Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G,: Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol 2010; 2: 68-75.
19. Jacquet P, Sugarbaker PH,: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-374.
20. Glehen O, Gilly FN,: Quantitative prognostic indicators of peritoneal surface malignancy: Carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 2003; 12: 649-671.
21. Glockzin G, Ghali N, Lang SA, et al.: Peritoneal carcinomatosis. Surgical treatment, including hyperthermic intraperitoneal chemotherapy. Chirurg 2007; 78: 1100-1110.
22. Glockzin G, Schlitt HJ, Piso P,: Peritoneal carcinomatosis: Patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2009; 7: 5.
23. Gusani NJ, Cho SW, Colovos C, et al.: Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008; 15: 754-763.
24. Glehen O, Osinsky D, Cotte E, et al.: Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: Morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10: 863-869.
25. Quenet F, Goere D, Mehta SS, et al.: Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 2011; 254: 294-301.
26. Stephens AD, Alderman R, Chang D, et al.: Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999; 6: 790-796.
27. Kusamura S, Younan R, Baratti D, et al.: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006; 106: 1144-1153.
28. Franko J, Gusani NJ, Holtzman MP, et al.: Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol 2008; 15: 3065-3072.
29. Elias D, Benizri E, Di Pietrantonio D, et al.: Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007; 14: 509-514.
30. Van der Speeten K, Stuart OA, Mahteme H, et al.: Pharmacology of perioperative 5-fluorouracil. J Surg Oncol 2010; 102: 730-735.
31. Ferron G, Dattez S, Gladieff L, et al.: Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol 2008; 62: 679-683.
32. Mahteme H, Wallin I, Glimelius B, et al.: Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol 2008; 64: 907-911.
33. Elias D, Bonnay M, Puizillou JM, et al.: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002; 13: 267-272.